On the Sidelines of His Participation in the 91st Edition of the China International Medical Equipment Fair (CMEF)
Egypt Healthcare Authority Chairman Conducts Field Visit to the World’s Largest Recombinant Human Albumin and Plasma Derivatives Production Facility Using Biotechnology
EHA Chairman: Biotech-Based Human Albumin and Plasma Derivatives Manufacturing Represents a Promising Future – We Aim to Transfer This Technology to Egypt in Collaboration with Chinese Partners
EHA Chairman: Key Areas of Collaboration with China's AnRat Group Include Localizing Biotechnology, Training Medical and Technical Cadres, and Exchanging Expertise in This Strategic Field
EHA Chairman: We Are Considering Signing a Memorandum of Understanding with AnRat Group to Position Egypt as a Regional and African Leader in Biotechnology
EHA Chairman: We Will Coordinate with Relevant Egyptian Authorities to Study the Adoption of Recombinant Biologics, Ensuring Full Compliance with Scientific, Clinical, and Regulatory Standards in Collaboration with the Egyptian Drug Authority
AnRat Group CEO: We Are Committed to Transferring and Localizing Recombinant Human Albumin and Plasma Derivatives Manufacturing Technologies to Egypt, and Empowering Egyptian Experts from the Healthcare Authority
AnRat Group CEO: Egypt’s Clear Vision for Healthcare Development Strengthens Our Confidence in Its Ability Not Only to Localize Biotech Industries but Also to Partner in Joint Research and Development
Dr. Ahmed El-Sobky, Chairman of the Egypt Healthcare Authority (EHA) and General Supervisor of the Universal Health Insurance Project, conducted a field visit to the world's largest factory for producing recombinant human albumin and plasma derivatives using biotechnology during his participation in the 91st edition of the China International Medical Equipment Fair (CMEF).
During the visit, Dr. El-Sobky met with Mr. Xiang Wei, CEO of AnRat Group, where both sides explored opportunities for collaboration in biomanufacturing and the localization of advanced technologies.
Dr. El-Sobky emphasized that manufacturing human albumin and plasma derivatives through biotechnology represents a promising future for medicine and therapy. He stated that EHA, in collaboration with Chinese partners, seeks to transfer these advanced technologies to Egypt to enhance national capabilities and achieve self-sufficiency in this vital and strategic field.
He added that the areas of cooperation with AnRat Group include the localization of biomanufacturing technologies in Egypt, training and qualifying medical and technical cadres, and exchanging expertise, contributing to building a sustainable healthcare system based on innovation and knowledge.
Dr. El-Sobky noted that the Authority is currently considering signing a Memorandum of Understanding (MoU) with AnRat Group to establish a strategic partnership, paving the way for Egypt to become a regional and African leader in biotechnology.
He further stated, “We will work with the relevant authorities in Egypt to study the feasibility of adopting recombinant biologic products, ensuring they meet all required scientific, clinical, and regulatory standards for quality and safety, in full coordination with the Egyptian Drug Authority.”
For his part, Mr. Xiang Wei, CEO of AnRat Group, expressed his enthusiasm for collaborating with Egypt to transfer and localize the manufacturing of recombinant human albumin and plasma derivatives, affirming their commitment to transferring biotechnology knowledge and techniques to experts and specialists within the Egypt Healthcare Authority.
He added, "What we witnessed today regarding Egypt's clear vision for healthcare development assures us of the country's potential not only to localize biotech industries but also to engage effectively in joint scientific research and development."
The visit was attended by:
From EHA: Dr. Amir El-Telwany, Executive Director of the Authority
From AnRat Group: Mr. Yang Tao, Deputy General Manager; Mr. Luke Liu, Executive Director of Quality; and Mr. Jie Chen, Director of Business Development
It is noteworthy that Dr. El-Sobky's visit to China forms part of a comprehensive program that includes field visits, international meetings, and exposure to the latest technological advancements in the medical and pharmaceutical sectors. The aim is to strengthen EHA’s leadership in adopting innovative healthcare models and integrate global best practices to improve the quality of life for Egyptian citizens.
CMEF is a prestigious global platform showcasing the latest innovations and technologies in healthcare, attracting visitors from over 150 countries, featuring advancements in artificial intelligence, robotic surgery, laboratory diagnostics, digital healthcare, and health infrastructure technologies.
